Genomic insights into a contagious cancer in Tasmanian devils

Trends in Genetics

Volumn 31, Issue 9, 2015, Pages 528-535

  Grueber, Catherine E ^a,b   Peel, Emma ^a   Gooley, Rebecca ^a   Belov, Katherine ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b INSTITUTE FOR CONSERVATION RESEARCH   (United States)

Author keywords

Cancer; Conservation; DFTD; Genomics; MHC; Tasmanian devil

Indexed keywords

ALLOGRAFT; CANCER GENETICS; CHROMOSOME 1; CONTAGIOUS CANCER; DEVIL FACIAL TUMOUR DISEASE; FACE TUMOR; GENE SEQUENCE; GENETIC VARIABILITY; IMMUNE RESPONSE; KARYOTYPE; MARKER CHROMOSOME; MARSUPIAL; MOLECULAR GENETICS; NEOPLASM; NONHUMAN; POPULATION GENETICS; PRIORITY JOURNAL; REVIEW; SCHWANN CELL; SPECIES EXTINCTION; TASMANIAN DEVIL; ANIMAL; ANIMAL DISEASE; FEMALE; GENETICS; GENOME; IMMUNOLOGY; MOLECULAR EVOLUTION; PATHOLOGY;

ANIMAL DISEASES; ANIMALS; EVOLUTION, MOLECULAR; EXTINCTION, BIOLOGICAL; FEMALE; GENOME; MARSUPIALIA; NEOPLASMS; SCHWANN CELLS;

EID: 84940889685     PISSN: 01689525     EISSN: 13624555     Source Type: Journal    
DOI: 10.1016/j.tig.2015.05.001     Document Type: Review

References (81)

1. Hawkins C.E., et al. Emerging disease and population decline of an island endemic, the Tasmanian devil Sarcophilus harrisii. Biol. Conserv. 2006, 131:307-324.
2. Owen D., Pemberton D. Tasmanian devil: a unique and threatened animal 2005, Allen & Unwin, Sydney.
3. Paddle R. The last Tasmanian tiger: the history and extinction of the thylacine 2000, Cambridge University Press, Cambridge.
4. Brown O.J.F. Tasmanian devil (Sarcophilus harrisii) extinction on the Australian mainland in the mid-Holocene: multicausality and ENSO intensification. Alcheringa 2006, 30:49-57.
5. Bradshaw C.J.A., Brook B.W. Disease and the devil: density-dependent epidemiological processes explain historical population fluctuations in the Tasmanian devil. Ecography 2005, 28:181-190.
6. Brüniche-Olsen A., et al. Extensive population decline in the Tasmanian devil predates European settlement and devil facial tumour disease. Biol. Lett. 2014, 10:20140619.
7. Morris K., et al. Low major histocompatibility complex diversity in the Tasmanian devil predates European settlement and may explain susceptibility to disease epidemics. Biol. Lett. 2013, 9:20120900.
8. Jones M.E., et al. Genetic diversity and population structure of Tasmanian devils, the largest marsupial carnivore. Mol. Ecol. 2004, 13:2197-2209.
9. Miller W., et al. Genetic diversity and population structure of the endangered marsupial Sarcophilus harrisii (Tasmanian devil). Proc. Nat. Acad. Sci. U.S.A. 2011, 108:12348-12353.
10. Siddle H.V., et al. MHC gene copy number variation in Tasmanian devils: implications for the spread of a contagious cancer. Proc. Biol. Sci. 2010, 277:2001-2006.
11. McCallum H. Tasmanian devil facial tumour disease: lessons for conservation biology. Trends Ecol. Evol. 2008, 23:631-637.
12. Lane A., et al. New insights into the role of MHC diversity in devil facial tumour disease. PLoS ONE 2012, 7:e36955.
13. Siddle H., et al. Transmission of a fatal clonal tumor by biting occurs due to depleted MHC diversity in a threatened carnivorous marsupial. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:16221.
14. Murchison E., et al. The Tasmanian devil transcriptome reveals Schwann cell origins of a clonally transmissible cancer. Science 2010, 327:84-87.
15. Hamede R.K., et al. Biting injuries and transmission of Tasmanian devil facial tumour disease. J. Anim. Ecol. 2013, 82:182-190.
16. Pyecroft S., et al. Towards a case definition for Devil Facial Tumour Disease: What is it?. Ecohealth 2007, 4:346-351.
17. Siddle H.V., et al. Reversible epigenetic down-regulation of MHC molecules by devil facial tumour disease illustrates immune escape by a contagious cancer. Proc. NatL. Acad. Sci. U.S.A. 2013, 110:5103-5108.
18. Deakin J.E., Belov K. A comparative genomics approach to understanding transmissible cancer in Tasmanian devils. Annu. Rev. Genomics Hum. Genet. 2012, 13:207-222.
19. McCallum H., et al. Distribution and impacts of Tasmanian devil facial tumor disease. Ecohealth 2007, 4:318-325.
20. Hawkins, C.E. et al. (2008) Sarcophilus harrisii. The IUCN Red List of Threatened Species. Version 2014.3 www.iucnredlist.org. Accessed: 15/4/2015.
21. Pearse A., Swift K. Allograft theory: transmission of devil facial-tumour disease. Nature 2006, 439:549.
22. Deakin J., et al. Genomic restructuring in the Tasmanian devil facial tumour: chromosome painting and gene mapping provide clues to evolution of a transmissible tumour. PLoS Genet. 2012, 8:e1002483.
23. Stephens P.J., et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011, 144:27-40.
24. Stratton M.R., et al. The cancer genome. Nature 2009, 458:719-724.
25. Murchison E.P., et al. Genome sequencing and analysis of the Tasmanian devil and its transmissible cancer. Cell 2012, 148:780-791.
26. Shay J.W., Wright W.E. Hayflick, his limit, and cellular ageing. Nat. Rev. Mol. Cell Biol. 2000, 1:72-76.
27. Ujvari B., et al. Telomere dynamics and homeostasis in a transmissible cancer. PLoS ONE 2012, 7:e44085.
28. Tovar C., et al. Tumor-specific diagnostic marker for transmissible facial tumors of Tasmanian devils: immunohistochemistry studies. Vet. Pathol. 2011, 48:1195-1203.
29. Ueda R., et al. Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:10746-10751.
30. Schickel R., et al. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 2008, 27:5959-5974.
31. Arroyo E.J., Scherer S.S. The molecular organisation of myelinating Schwann cells. The biology of schwann cells 2007, 37-54. Cambridge University Press. P.J. Armati (Ed.).
32. Griffin J.W., Thompson W.J. Biology and pathology of nonmyelinating Schwann cells. Glia 2008, 56:1518-1531.
33. Armati P.J., Mathey E.K. An update on Schwann cell biology - immunomodulation, neural regulation and other surprises. J. Neurol. Sci. 2013, 333:69-72.
34. Lisak R.P., Benjamins J.A. Cytokine and chemokine interactions with Schwann cells: the neuroimmunology of Schwann cells. The biology of schwann cells 2007, 100-117. Cambridge University Press. P.J. Armati (Ed.).
35. Lee P.R., et al. Immune system evasion by peripheral nerve sheath tumor. Neurosci. Lett. 2006, 397:126-129.
36. Bender H.S., et al. Pathogenesis and molecular biology of a transmissible tumor in the Tasmanian devil. Annu. Rev. Anim. Biosci. 2014, 2:165-187.
37. Howson L.J., et al. Identification of dendritic cells, B cell and T cell subsets in Tasmanian devil lymphoid tissue; evidence for poor immune cell infiltration into devil facial tumors. Anat. Rec. 2014, 297:925-938.
38. Siddle H.V., Kaufman J. Immunology of naturally transmissible tumours. Immunology 2015, 144:11-20.
39. Woods G., et al. The immune response of the Tasmanian devil (Sarcophilus harrisii) and devil facial tumour disease. Ecohealth 2007, 4:338-345.
40. Kreiss A., et al. Evidence for induction of humoral and cytotoxic immune responses against devil facial tumor disease cells in Tasmanian devils (Sarcophilus harrisii) immunized with killed cell preparations. Vaccine 2015, 10.1016/j.vaccine.2015.1001.1039.
41. Bodduluru L.N., et al. Natural killer cells: The journey from puzzles in biology to treatment of cancer. Cancer Lett. 2015, 357:454-467.
42. Brown G.K., et al. Natural killer cell mediated cytotoxic responses in the Tasmanian devil. PLoS ONE 2011, 6:e24475.
43. van der Kraan L.E., et al. Identification of natural killer cell receptor genes in the genome of the marsupial Tasmanian devil (Sarcophilus harrisii). Immunogenetics 2013, 65:25-35.
44. Pleasance E.D., et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010, 463:191-196.
45. Pleasance E.D., et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010, 463:184-190.
46. Ley T.J., et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008, 456:66-72.
47. Ding L., et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010, 464:999-1005.
48. Pearse A-M., et al. Evolution in a transmissible cancer: a study of the chromosomal changes in devil facial tumor (DFT) as it spreads through the wild Tasmanian devil population. Cancer Genet. 2012, 205:101-112.
49. Ujvari B., et al. Evolution of a contagious cancer: epigenetic variation in devil facial tumour disease. Proc. Biol. Sci. 2013, 280:20121720.
50. Ujvari B., et al. Anthropogenic selection enhances cancer evolution in Tasmanian devil tumours. Evol. App. 2014, 7:260-265.
51. Otto S.P. The evolutionary consequences of polyploidy. Cell 2007, 131:452-462.
52. Lachish S., et al. Evaluation of selective culling of infected individuals to control Tasmanian devil facial tumor disease. Conserv. Biol. 2010, 24:841-851.
53. Castedo M., et al. Selective resistance of tetraploid cancer cells against DNA damage-induced apoptosis. Ann. N. Y. Acad. Sci. 2006, 1090:35-49.
54. Davoli T., de Lange T. The causes and consequences of polyploidy in normal development and cancer. Annu. Rev. Cell Dev. Biol. 2011, 27:585-610.
55. CSBG Tasmanian devil PHVA final report 2008, IUCN/SSC Conservation Breeding Specialist Group, Apple Valley, MN.
56. Lees C., Andrew P. The Tasmanian devil insurance meta-population: 2012 evaluation and review 2012, IUCN/SSC Conservation Breeding Specialist Group, Apple Valley, MN.
57. Sinn D.L., et al. Save the Tasmanian Devil Program free-range project, annual report January - December 2009: Initial results from the first year's breeding season and recommendations for future planning 2010, Department of Primary Industries, Parks, Water and Environment, Hobart.
58. Ballou J.D., et al. Demographic and genetic management of captive populations. Wild Mammals in Captivity: Principles and Techniques for Zoo Management 2010, 219-252. University of Chicago Press. 2nd edn. D.G. Kleiman (Ed.).
59. Lacy R.C. Clarification of genetic terms and their use in the management of captive populations. Zoo Biol. 1995, 14:565-577.
60. Lacy R.C. Analysis of founder representation in pedigrees: founder equivalents and founder genome equivalents. Zoo Biol. 1989, 8:111-123.
61. McGlashan N.D., et al. Aspects of the fatal malignant disease among the Tasmanian devil population (Sarcophilus laniarius). Eur. J. Oncol. 2006, 11:95-102.
62. Blouin M.S. DNA-based methods for pedigree reconstruction and kinship analysis in natural populations. Trends Ecol. Evol. 2003, 18:503-511.
63. Guichoux E., et al. Current trends in microsatellite genotyping. Mol. Ecol. Resour. 2011, 11:591-611.
64. Cheng Y., Belov K. Characterisation of non-classical MHC class I genes in the Tasmanian devil (Sarcophilus harrisii). Immunogenetics 2014, 66:727-735.
65. Cheng Y., et al. Low MHC class II diversity in the Tasmanian devil (Sarcophilus harrisii). Immunogenetics 2012, 64:525-533.
66. Siddle H., et al. Characterization of major histocompatibility complex class I and class II genes from the Tasmanian devil (Sarcophilus harrisii). Immunogenetics 2007, 59:753.
67. Cui J., et al. Diversity in the Toll-like receptor genes of the Tasmanian devil (Sarcophilus harrisii). Immunogenetics 2015, 67:195-201.
68. Acevedo-Whitehouse K., Cunningham A.A. Is MHC enough for understanding wildlife immunogenetics?. Trends Ecol. Evol. 2006, 21:433-438.
69. Ingram J., Kirkpatrick J.B. Native vertebrate herbivores facilitate native plant dominance in old fields while preventing native tree invasion - implications for threatened species. Pac. Conserv. Biol. 2013, 19:331-342.
70. Rounsevell D., et al. Distribution records of native terrestrial mammals in Tasmania. Wildl. Res. 1991, 18:699-717.
71. DPIPWE Save the Tasmanian Devil Program 2012-13 annual program report 2013, Department of Primary Industries, Parks, Water and Environment, Hobart.
72. Shafer A.B.A., et al. Genomics and the challenging translation into conservation practice. Trends Ecol. Evol. 2015, 30:78-87.
73. Toro M.A., et al. Genomics applied to management strategies in conservation programmes. Livest. Sci. 2014, 166:48-53.
74. DPIPWE New phase of the Save the Tasmanian Devil Program 2014, Department of Primary Industries, Parks, Water and Environment, Accessed: 14/04/2015. http://www.tassiedevil.com.au/tasdevil.nsf/news/9D8843A45A376952CA257D9B00143EC1.
75. Doherty P.C., Zinkernagel R.M. A biological role for the major histocompatibilty complex. Lancet 1975, 1:1406-1409.
76. Campoli M., Ferrone S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 2008, 27:5869-5885.
77. Lehner P.J., Cresswell P. Processing and delivery of peptides presented by MHC class I molecules. Curr. Opin. Immunol. 1996, 8:59-67.
78. Madden D.R. The three-dimensional structure of peptide-MHC complexes. Annu. Rev. Immunol. 1995, 13:587-622.
79. Berger S.L. Histone modifications in transcriptional regulation. Curr. Opin. Genet. Dev. 2002, 12:142-148.
80. Garcia K.C., et al. An αβ T cell receptor structure at 2.5Å and its orientation in the TCR-MHC complex. Science 1996, 274:209-219.
81. Dustin M.L., Chan A.C. Signaling takes shape in the immune system. Cell 2000, 103:283-294.